Brief reportPrognostic differences between atrial fibrillation and atrial flutter☆
References (15)
- et al.
Influence of etiology of atrial fibrillation on incidence of systemic embolism
Am J Cardiol
(1977) - et al.
Thromboembolism in chronic atrial flutteris the risk underestimated?
J Am Coll Cardiol
(1997) - et al.
Thromboembolism following cardioversion of “common” atrial flutterrisk factors and limitations of transesophageal echocardiography
Chest
(1996) - et al.
Risk of thromboembolism in chronic atrial flutter
Am J Cardiol
(1997) - et al.
Risk of thromboembolic events in patients with atrial flutter
Am J Cardiol
(1998) - et al.
Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillationidentification of a subgroup of patients at increased embolic risk
J Am Coll Cardiol
(1994) - et al.
Left atrial appendage Doppler flow patternsimplications on thrombus formation
Am Heart J
(1992)
Cited by (43)
Atrial Tachycardia—Mechanisms and Management
2017, Encyclopedia of Cardiovascular Research and MedicineTrends in atrial flutter and atrial tachycardia research
2017, Informatics in Medicine UnlockedCitation Excerpt :During this year, a number of didactic, quantitative studies were published which may have contributed to the spike. These include histories of atrial flutter treatment [19], catheter ablation of atrial flutter [20], mapping and anatomy of atrial flutter [21,22], electrogram characteristics [23], and comparisons between atrial flutter and atrial fibrillation [24,25]. The method used for quantitative analysis in this study included both the MEDLINE search tool and an in-house developed computer program.
Atrial flutter: Clinical risk factors and adverse outcomes in the Framingham Heart Study
2016, Heart RhythmCitation Excerpt :Our findings support previous studies demonstrating that the occurrence of AF in follow-up is common in individuals with a history of flutter.27,28 Similarly, the presence of left atrial appendage thrombus29 and increased risk of stroke associated with flutter also have been previously described,27,30 and professional management guidelines8 for anticoagulation in flutter and AF are similar. The underlying pathology of stroke in flutter is complicated, given that atrial thrombus formation is believed to be due to lack of organized atrial activity in AF.
Serum potassium levels and the risk of atrial fibrillation: The Rotterdam Study
2013, International Journal of CardiologyCitation Excerpt :Atrial fibrillation occurring during a serious disease resulting in death, during myocardial infarction or during cardiac operative procedures of patients who recovered during the hospital admission was not included as cases. We did not distinguish between atrial fibrillation and atrial flutter when we identified cases because both conditions are very similar with respect to risk factors and consequences [19,20]. Age at baseline and sex were included in all analyses.
Unrecognized myocardial infarction and risk of a trial fibrillation: The Rotterdam study
2013, International Journal of CardiologyGuidelines for performing a comprehensive transesophageal echocardiographic examination: Recommendations from the american society of echocardiography and the society of cardiovascular anesthesiologists
2013, Journal of the American Society of EchocardiographyCitation Excerpt :There are some thrombi, however, that do not appear well circumscribed but have spontaneous echocardiographic contrast surrounding an organized portion; in these instances, prolonged observation in a single plane or using simultaneous multiple-plane imaging may be required to differentiate sludge from thrombus. Doppler of the LA appendage can be performed, particularly in the setting of atrial fibrillation or atrial flutter, to assess the risk for thrombus formation, because flow velocity at the ostium has significant prognostic utility.138 The pulsed Doppler sample volume is typically placed 1 to 2 cm from the orifice within the chamber (Figures 15A and 15B).
- ☆
This research was supported by an unrestricted grant from Procter and Gamble Pharmaceutical Canada Inc., Mason, Ohio.